摘要
类风湿性关节炎是一种慢性自身免疫性疾病,其特征是炎症、肿胀和关节破坏,主要影响周围关节。近年来,类风湿关节炎已成为一个令人担忧的问题,影响着全球超过1.5%的人口。在类风湿关节炎的临床试验中,大多数药物都是免疫调节剂。RA新药的开发迫在眉睫,科学家们正在通过各种创新的方法来探索RA新药开发的新策略。治疗-靶向和机会之窗假说分别是用于治疗、改善疗效和防止长期使用无效治疗的新方法。新型治疗药物(如GM-CSF抑制剂、基质金属蛋白酶抑制剂)和传递系统(如脂质体、超顺磁氧化铁纳米颗粒(SPIONs))正在研究中,以获得更靶向的治疗,减少副作用和毒性。新药物的发现和重新定位之前fda批准的药物也被考虑用于慢性炎症疾病。本综述包含了大量的信息,包括遗传学、病因学、临床症状、当前治疗和新的治疗方法,重点关注RA干预的发展。本综述还重点讨论了基于生物信息学的方法在RA中的应用。这篇综述提供了对类风湿性关节炎治疗中的挑战和不确定性的总体理解,并总结了类风湿性关节炎药物开发的发展情况和创新方法。
关键词: 类风湿性关节炎,自身免疫性疾病,炎症,靶向治疗,生活方式管理,生物信息学
Current Drug Targets
Title:A Review on Rheumatoid Arthritis Interventions and Current Developments
Volume: 22 Issue: 4
关键词: 类风湿性关节炎,自身免疫性疾病,炎症,靶向治疗,生活方式管理,生物信息学
摘要: Rheumatoid arthritis is a chronic autoimmune disorder characterized by inflammation, swelling, and joint destruction primarily affecting the peripheral joints. In recent years, RA has become an alarming concern affecting more than 1.5% of the population worldwide. The majority of the drugs in clinical trials for rheumatoid arthritis are immunomodulatory. The development of novel drugs for RA is impending and scientists are exploring new strategies through various innovative approaches for RA drug development. Treat-to-target and window of opportunity hypothesis are the new approaches that are used to treat, improve outcomes, and prevent long-term use of ineffective therapy, respectively. Novel therapeutic agents (e.g. GM-CSF inhibitors, Matrix metalloproteinase inhibitors) and delivery systems (e.g., Liposomes, Superparamagnetic iron oxide nano particles (SPIONs)) are under investigation for more target based therapy with reduced side effects and toxicity. The new drug discovery and repositioning of previously FDA-approved drugs are also being considered for chronic inflammatory disorder. The review encompasses a vast array of information, including genetics, etiology, clinical symptoms, current treatment, and newer therapeutics approaches, focused on the development of RA interventions. The introduction of the bioinformatics-based approach in RA has also been significantly discussed in the review. This review provides a general understanding of the challenges and uncertainties in the treatment of RA and summarizes the evolving scenario as well as innovative approaches taken into consideration for drug development in rheumatoid arthritis.
Export Options
About this article
Cite this article as:
A Review on Rheumatoid Arthritis Interventions and Current Developments, Current Drug Targets 2021; 22 (4) . https://dx.doi.org/10.2174/1389450121999201125200558
DOI https://dx.doi.org/10.2174/1389450121999201125200558 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Fibrates and Microvascular Complications in Diabetes - Insight from the FIELD Study
Current Pharmaceutical Design Resveratrol and Cardiovascular Disease
Current Nutrition & Food Science Review of Endocrine Manifestations of Antiphospholid Syndrome
Current Rheumatology Reviews Targeting TNF-Alpha in HIV-1 Infection
Current Drug Targets Disease Modifying Approaches for Alzheimers Pathology
Current Pharmaceutical Design Novel Drug Targets for the Treatment of Cardiac Diseases
Current Pharmacogenomics and Personalized Medicine Adhesion Dependent Signalling in the Tumour Microenvironment: The Future of Drug Targetting
Current Pharmaceutical Design Local Activation and Systemic Dysregulation of T Lymphocytes in Sjögren’s Syndrome
Current Pharmaceutical Biotechnology Novel Therapeutic Targets for Somatostatin in Inflammatory Chronic Diseases
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Role of Alpha-1 Antitrypsin (AAT) in Ocular Allergy and Uveitis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Animal Models of Lupus and Lupus Nephritis
Current Pharmaceutical Design PPARs as Drug Targets to Modulate Inflammatory Responses?
Current Drug Targets - Inflammation & Allergy Randomized Controlled Trials in Steroid Dependent and in Severe Colitis
Reviews on Recent Clinical Trials Epigenetic control of cardiovascular health by nutritional polyphenols involves multiple chromatin-modifying writer-reader-eraser proteins
Current Topics in Medicinal Chemistry High-Resolution CT Imaging Findings of Collagen Vascular Disease- Associated Interstitial Lung Disease
Current Respiratory Medicine Reviews Hydroximic Acid Derivatives: Pleiotropic Hsp Co-Inducers Restoring Homeostasis and Robustness
Current Pharmaceutical Design Editorial (Thematic Issue: Is The Female Heart Exposed To Cardiovascular Disease?)
Current Medicinal Chemistry Susceptibility Genes in Hypertension
Current Pharmaceutical Design Anti-Angiogenic Therapy: Strategies to Develop Potent VEGFR-2 Tyrosine Kinase Inhibitors and Future Prospect
Current Medicinal Chemistry Natural Products and Cancer Stem Cells
Current Pharmaceutical Design